Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA™ Phase 1 heme trial to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of the heme program and initiate preclinical development of in vivo-engineered TCR-T for solid tumors Cash, cash equivalents, and marketable securities expected to fund operations into the second half of 2027 WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the third quarter ended...

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026   Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported...

AleAnna, Inc. Reports Positive Net Income, EBITDA, EPS and Cash from Operations in Third Quarter 2025 Third Quarter 2025 Results and Recent Company Highlights:AleAnna generated $5.3 million of net income and $6.3 million of EBITDA(1) in the third quarter driven by strong production at the Longanesi field generating $11.2 million of revenue in the quarter AleAnna reported basic and diluted net income per share of class A common stock of $0.08 for the quarter ended September 30, 2025 AleAnna generated $8.9 million of cash from operations during the third quarter and closed the period with a strong cash position of approximately $31.2 million.DALLAS, Nov. 12, 2025 (GLOBE NEWSWIRE) — AleAnna, Inc. (“AleAnna” or “the Company”) (NASDAQ: ANNA) today announced financial and operational results for the third quarter of 2025. AleAnna...

– Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement –  – Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – – Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations – – Conference call today at 8:00 am ET – DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the third quarter ended September 30, 2025, and provided...

$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory Skin Disease Summit (ISDS) Strengthened leadership team and board with addition of Dr. Kristin Yarema as Chief Executive Officer, Dr. Kurinji Pandiyan as Chief Strategy and Operations Officer, Dr. Renuka Sivendran as Chief Technical Officer, and Joe Slattery as an independent director SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), a clinical-stage biotechnology...

Revenues Increased by 58%, GAAP Operating Income Rose to $7.5 Million, Adjusted EBITDA Grew to $15.6 Million Raising Midpoint of 2025 Revenue and Adjusted EBITDA Guidance PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the third quarter, ended September 30, 2025. Third Quarter 2025 Financial HighlightsRevenues of $117.7 million, compared with $74.6 million in Q3 2024; GAAP operating income of $7.5 million, compared with GAAP operating income of $6.7 million in Q3 2024; Non-GAAP operating income of $12.8 million, compared with $8.3 million in Q3 2024; GAAP net income of $8.1 million, or $0.14 per diluted share, compared with GAAP net income of $6.8 million,...

– Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – – Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 development for progressive forms of Multiple Sclerosis (MS) – – Entered into obexelimab funding agreement with Royalty Pharma for up to $300.0 million, including $75M upfront, to support clinical development and potential commercial launch – WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical...

–   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end –   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders –   Ended Q3 with $42.7 million of cash with expected runway into 2027 LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2025, and provided a business update. “With a continued commitment to advancing OLC, we are poised...

Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today reported its financial results for third quarter ended September 30, 2025,...

PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential FDA Approval $82.6 million in Cash at September 30; Successful Equity Offering and Amended Royalty Purchase Agreement Provide Resources for Successful Launch  MONTREAL and CHARLOTTE, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ending September 30, 2025, and provided corporate and regulatory updates. “We are approaching our December 13 Prescription Drug User Fee Act (PDUFA) date with optimism and excitement for the opportunity to bring CARDAMYST (etripamil) nasal spray to patients suffering from symptomatic PSVT,” said Joseph Oliveto,...